Antibody-directed enzyme-prodrug therapy (ADEPT)

Drugs of the Future

Volumn 21, Issue 9, 1996, Pages 917-931

  Hay, Michael P ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBODY CONJUGATE; BETA GLUCURONIDASE; BETA LACTAMASE; CARBOPLATIN; CARBOXYPEPTIDASE G2; CEPHALOSPORIN DERIVATIVE; CYTOSINE DEAMINASE; DOXORUBICIN DERIVATIVE; ETOPOSIDE DERIVATIVE; IMMUNOTOXIN; MELPHALAN DERIVATIVE; METHOTREXATE DERIVATIVE; MITOMYCIN C DERIVATIVE; MONOCLONAL ANTIBODY; NITROREDUCTASE; NITROSOUREA DERIVATIVE; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG; VINCA ALKALOID;

CANCER; DRUG MANUFACTURE; DRUG TARGETING; HUMAN; IMMUNOTHERAPY; REVIEW; TECHNIQUE; THEORY;

EID: 0029803995     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.09.880186     Document Type: Review

References (92)

1. Winter, G., Milstein, C. Man-made antibodies. Nature 1991, 349: 293-9.
2. Pietersz, G.A., McKenzie, I.F. Antibody conjugates for the treatment of cancer. Immunol Rev 1992, 129: 57-80.
3. Vitetta, E.S., Thorpe, P.E., Uhr, J.W. Immunotoxins: Magic bullets or misguided missiles? Immunol Today 1993, 14: 252-9.
4. Jungheim, L.N., Shepherd, T.A. Design of antitumor prodrugs: Substrates for antibody targeted enzymes. Chem Rev 1994, 94: 1553-6.
5. Bagshawe, K.D. The first Bagshawe lecture. Towards generating cytotoxic agents at cancer sites. Brit J Cancer 1989, 60: 275-81.
6. Melton, R.G., Sherwood, R.F. Antibody-enzyme conjugates for cancer therapy. J Natl Cancer Inst 1996, 88: 153-65.
7. Niculescu-Duvaz, I., Springer, C.J. Development of prodrugs for ADEPT (antibody-directed enzyme prodrug therapy). Exp Opin Invest Drugs 1996, 3: 289-308.
8. Niculescu-Duvaz, I., Springer, C.J. Antibody-directed enzyme prodrug therapy (ADEPT): A targeting strategy in cancer chemotherapy. Curr Med Chem 1995, 2: 687-706.
9. Heunnekens, F.M. Tumor targeting: Activation of prodrugs by enzyme-monoclonal antibody conjugates. Trends Biotechnol 1994, 12: 234-9.
10. Bagshawe, K.D., Sharma, S.K., Springer, C.J., Rogers, G.T. Antibody directed enzyme prodrug therapy (ADEPT): A review of some theoretical, experimental and clinical aspects. Ann Oncol 1994, 5: 879-91.
11. Bagshawe, K.D. Antibody-directed enzyme prodrug therapy: A review. Drug Dev Res 1995, 34: 220-30.
12. Jain, R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990, 50 (Suppl): 814-9.
13. Jain, R.K., Baxter, LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumours: Significance of elevated interstitial pressure. Cancer Res 1988, 48: 7022-32.
14. Ward, B.C., Mather, S.J., Hawkins, L.R. et al. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: Assessment of intravenous and intraperitoneal routes of administration. Cancer Res 1987, 47: 4719-23.
15. Welt, S., Divgi, C.R., Real, F.X. et al. Quantitative analysis of antibody localization in human metastatic colon cancer: A phase I study of monoclonal antibody A33. J Clin Oncol 1990, 8: 1894-906.
16. Muraro, R., Frati, L., Bei, R. et al. Regional heterogeneity and complementation in the expression of the tumour-associated glycoprotein 72 epitopes in colorectal cancer. Cancer Res 1991, 51: 5378-83.
17. Reilly, R.M., Sanhu, J., Alvarez-Díez, T.M., Gallinger, S., Kirsh, J., Stern, H. Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions. Clin Pharmacokinet 1995, 28: 126-42.
18. Yuan, F., Baxter, L.T., Jain, R.K. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991, 51: 3119-30.
19. Baxter, L.T., Jain, R.K. Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: Comparison with experimental data. Brit J Cancer 1996, 73: 447-56.
20. Senter, P.D., Wallace, P.M., Svensson, H.P. et al. Generation of cytotoxic agents by targeted enzymes. Bioconj Chem 1993, 4: 3-9.
21. Sharma, S.K., Bagshawe, K.D., Burke, P.J., Boden, R.W., Rogers, G.T. Inactivation and clearance of an anti-CEA carboxypeptidase G2 conjugate in blood after localisation in a xenograft model. Brit J Cancer 1990, 61: 659-62.
22. Wallace, P.M., MacMaster, J.F., Smith, V.F., Kerr, D.E., Senter, P.D., Cosand, W.L. Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine. Cancer Res 1994, 54: 2719-23.
23. Mauger, A.B., Burke, P.B., Somani, H.H., Freidlos, F, Knox, RJ. Self-immolative prodrugs: Candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J Med Chem 1994, 37: 3452-8.
24. Denny, W.A., Wilson, W.R., Hay, M.P. Recent developments in the design of bioreductive drugs. Brit J Cancer 1996, 74(Suppl. 27): 532-8.
25. Blakey, D.C., Burke, P.J., Davies, D.H. et al. Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease. Biochem Soc Trans 1995, 23: 1047-50.
26. Bagshawe, K.D. Antibody directed enzymes revive anti-cancer prodrugs concept. Brit J Cancer 1987, 56: 531-2.
27. Bagshawe, K.D., Springer, C.J., Searle, F. et al. A cytotoxic agent can be generated selectively at cancer sites. Brit J Cancer 1988, 58: 700-3.
28. Springer, C.J., Antoniw, P., Bagshawe, K.D., Searle, F., Bisset, G.M., Jarman, M. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J Med Chem 1990, 33: 677-81.
29. Springer, C.J., Antoniw, P., Bagshawe, K.D., Wilman, D.E. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des 1991, 6: 467-79.
30. Springer, C.J., Bagshawe, K.D., Sharma, S.K. et al. Ablation of human choriocarcinoma xenografts in nude mice by an antibody-directed enzyme prodrug therapy with three novel compounds. Eur J Cancer 1991, 21: 1361-6.
31. Sharma, S.K., Bagshawe, K.D., Springer, C.J. et al. Antibody directed enzyme prodrug therapy (ADEPT): A three phase system. Disease Markers 1991, 9: 225-31.
32. Blakey, D.C., Valcaccia, B.E., East, S. et al. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with benzoic acid mustard prodrug. Cell Biophys 1993, 22: 1-8.
33. Sharma, S.K. Bagshawe, K.D., Burke, P.J. et al. Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy. Cancer 1994, 73 (Suppl): 1114-20.
34. Melton, R.G., Rowland, J.A., Pietersz, G.A., Sherwood, R.F., McKenzie, I.F. Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate. Eur J Cancer 1993, 29A; 1177-83.
35. Sharma, S.K., Boden, J.A., Springer, C.J., Burke, P.J., Bagshawe, K.D. Antibody-directed enzyme prodrug therapy (ADEPT): A three phase study in ovarian tumor xenografts. Cell Biophys 1994, 24/25: 219-28.
36. Bagshawe, K.D., Sharma, S.K., Springer, C.J. et al. Antibody-enzyme conjugates can generate cytotoxic drugs from inactive precursors at tumor sites. Antibody Immunoconj Radiopharm 1991, 4: 915-22.
37. Springer, C.J., Niculescu-Duvaz, I., Pedley, B.R. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. J Med Chem 1994, 37: 2361-70.
38. Springer, C.J., Niculescu-Duvaz, I. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Des 1995, 10: 361-72.
39. Springer, C.J., Dowell, R., Burke, P.J. et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1995, 38: 5051-65.
40. Dowell, R.I., Springer, C.J., Davies, D.H. et al. New mustard prodrugs for antibody-directed enzyme prodrug therapy: Alternatives to the amide link. J Med Chem 1996, 39: 1100-5.
41. Blakey, D.C., Burke, P.J., Davies, D.H. et al. ZD2767, a new adept system which results in tumour regressions in colorectal tumour xenografts. Brit J Cancer 1995, 71 (Suppl): 12.
42. Blakey, D.C., Davies, D.H., Dowell, R.I. et al. Antitumoureffects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Brit J Cancer 1995, 72: 1083-8.
43. 1H NMR of cephalosporoate intermediates in aqueous solution during the hydrazinolysis and β-lactamase-catalysed hydrolysis of cephalosporins with 3′ leaving groups: Kinetics and equilibria of the 3′ elimination reaction. J Amer Chem Soc 1986, 108: 5328-33.
44. Faraci, W.S., Pratt, R.F. Mechanism of inhibition of RTEM-2 β-lactamase by cephamycins: Relative importance of the 7α-methoxy group and the 3′ leaving group. Biochemistry 1986, 25: 2934-41.
45. Albrecht, H.A., Beskid, G., Chan, K-K. et al. Cephalosporin 3′-quinolone esters with a dual mode of action. J Med Chem 1990, 33: 77-86.
46. Svensson, H.P., Kadow, J.F., Vrudhula, V.M., Wallace, P.M., Senter, P.D. Monoclonal antibody-β-lactamase conjugates for the activation of a cephalosporin mustard prodrug. Bioconj Chem 1992, 3: 176-81.
47. Vrudhula, V.M., Svennson, H.P., Kennedy, K.A., Senter, P.D., Wallace, P.M. Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-β-lactamase conjugates. Bioconj Chem 1993, 4: 334-40.
48. Sharma, S.K., Bagshawe, K.D., Melton, R.G. Immunogenicity of antibody-enzyme conjugates in antibody directed enzyme prodrug therapy. Antibody Immunoconj Radiopharm 1991, 4: 226.
49. Shepherd, T.A., Jungheim, L.N., Meyer, D.L., Starling, J.J. A novel targeted delivery system utilizing a cephalosporin-oncolytic prodrug activated by an antibody β-lactamase conjugate for the treatment of cancer. Bioorg Med Chem Lett 1991, 1: 21-6.
50. Jungheim, L.A., Shepherd, T.A., Meyer, D.L. Synthesis of acylhydrazido-substituted cephems. Design of cephalosporin-vinca alkaloid prodrugs: Substrates for an antibody-targeted enzyme. J Org Chem 1992, 57: 2334-40.
51. Meyer, M.L., Jungheim, L.N., Mikolajczyk, S.D., Shepherd T.A., Starling, J.J., Ahlem, C.N. Preparation and characterization of a beta-lactamase-Fab' conjugate for the site-specific activation of oncolytic agents. Bioconj Chem 1992, 3: 42-8.
52. Meyer, M.L., Jungheim, L.N. Law, K.L. et al. Site-specific prodrug activation by antibody-β-lactamase conjugates: Regression and long-term growth inhibition of human colon carcinoma xenograft models. Cancer Res 1993, 53: 3956-63.
53. Svennson, H.P., Vrudhula, V.M., Emswiler, J.E. et al. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody β-lactamase conjugates. Cancer Res 1995, 55: 2357-65.
54. Vrudhula, V.M., Svennson, H.P., Senter, P.D. Cephalosporin derivatives of doxorubicin as prodrugs for activation by monoclonal antibody-β-lactamase conjugates. J Med Chem 1995, 38: 1380-5.
55. Senter, P.D., Svennson, H.P., Schreiber, G.J., Rodríguez, J.L., Vrudhula, V.M. Poly(ethylene glycol)doxorubicin conjugates containing β-lactamase-sensitive linkers. Bioconj Chem 1995, 6: 389-94.
56. Meyer, D.L., Law, K.L., Kindle Payne, J. et al. Site-specific prodrug activation by β-lactamase conjugates: Preclinical investigation of the efficacy and toxicity of doxorubicin delivered by antibody directed catalysis. Bioconj Chem 1995, 6: 440-6.
57. Conners, T.A., Whisson, M.E. Cure of mice bearing advanced plasma cell tumours with aniline mustard: the relationship between glucuronidase activity and tumour sensitivity. Nature 1966, 210: 866-7.
58. Conners, T.A., Farmer, P.B., Foster, A.B., Gilsenan, A.M., Jarman, M., Tisdale, M.J. Metabolism of aniline mustard [N,N-di-(2-chloroethyl)aniline]. Biochem Pharmacol 1973, 22: 1971-80.
59. Kyle, R.A., Costa, G., Cooper, R.M. et al. Evaluation of aniline mustard in patients with multiple myeloma. Cancer Res 1973, 33: 956-60.
60. Young, C.W., Yagoda, A., Bittar, E.S., Smith, S.W., Grabstald, H., Whitmore, W. Therapeutic trial of aniline mustard in patients with advanced cancer. Cancer 1976, 38: 1887-95.
61. Wang, S-M., Chern, J-W., Yeh, M-Y, Ng, J.C., Tung, E., Roffler, S.R. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy. Cancer Res 1992, 52: 4484-91.
62. Jungheim, L.N., Shepherd, T.A. Design of antitumor prodrugs: Substrates for antibody targeted enzymes. Chem Rev 1994, 94: 1553-66.
63. Roffler, S.F., Wang, S-M., Chern, J-W., Yeh, M-Y., Tung, E. Antineoplastic glucuronide prodrug treatment of human tumor cells targeted with a monoclonal antibody-enzyme conjugate. Biochem Pharmacol 1991, 42: 2062-5.
64. Haisma, H.J., Boven, E., van Muijen, M., de Jong, J., van der Vijgh, W.J., Pinedo, H.M. A monoclonalantibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer. Brit J Cancer 1992, 66: 474-8.
65. Haisma, H.J., van Muijen, M., Pinedo, H.M., Boven, E. Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophys 1994, 24/25: 185-92.
66. Houba, P.H., Boven, E., Leenders, R.G., Scheeren, J.W., Pinedo, H.M., Haisma, H.J. A conjugate between deglycosylated human β-glucuronidase and the anti-pancarcinoma monoclonal antibody 323/A3 for activation of a daunorubicin prodrug in antibody-directed enzyme prodrug therapy (ADEPT). Proc Amer Assoc Cancer Res 1996, 37: Abst 3221.
67. Haisma, H.J., Sernee, F, Brakenhoff, R.H., van der Meulen-Muileman, I., Pinedo, H.M., Boven, E. Construction and characterization of a single chain human β-glucuronidase-anti-CD20 antibody fusion protein for antibody-directed enzyme prodrug therapy (ADEPT). Proc Amer Assoc Cancer Res 1996, 37: Abst 3222.
68. Haisma, H.J., van Muijen, M., Scheffer, G., Scheper, R.J., Pinedo, H.M., Boven, E. A monoclonal antibody against human β-glucuronidase for application in antibody-directed enzyme prodrug therapy. Hybridoma 1995, 14: 377-82.
69. Senter, P.D., Saulnier, M.G., Schreiber, G.J. et al. Antitumour effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate. Proc Natl Acad Sci USA 1988, 85: 4842-6.
70. Senter, P.D. Activation of prodrugs by antibody-enzyme conjugates: A new approach to cancer therapy. FASEB J 1990, 4: 188-93.
71. Senter. P.D., Schreiber, G.J., Hirschberg, D.L., Ashe, S.A., Hellstrom, K.E., Hellstrom, I. Enhancement of the in vitro and in vivo antitumour activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates. Cancer Res 1989, 49: 5789-92.
72. Sahin, U., Hartmann, F., Senter, P. et al. Specific activation of the prodrug mitomycin phosphate by a specific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 1990, 50: 6944-8.
73. Wallace, P.M., Senter P.D. In vitro and in vivo effects of antibody-alkaline phosphatase conjugates in combination with phenol mustard phosphate. Bioconj Chem 1991, 2: 349-52.
74. Schacter, L.P, Igwemezie, L.N., Seyedsadr, M. et al. Clinical and pharmacokinetic overview of parenteral etoposide phosphate. Cancer Chemother Pharmacol 1994, 34 (Suppl): 58-63.
75. Wallace, P.M., Senter, P.D. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Meth Find Exp Clin Pharmacol 1994, 17: 505-12.
76. Senter, P.D., Su, P.C., Katsuragi, T. et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates. Bioconj Chem 1991, 2: 447-51.
77. Anlezark, G.M., Melton, R.G., Sherwood, R.F., Coles, B., Freidlos, F., Knox, R.J. The bioactivation of 5-(aziridin-l-yl)-2,4-dinitrobenzamide(CB 1954) I. Purification and properties of a nitroreductase enzyme from Escherichia coli - a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1992, 44: 2289-95.
78. Freidlos, F., Knox, R.J. Metabolism of NAD(P)H by blood components. Relevance to bioreductively activated prodrugs in a targeted enzyme therapy system. Biochem Pharmacol 1992, 44: 631-5.
79. Freidlos, F., Jarman, M., Davies, L.C., Boland, M.P., Knox, R.J. Identification of novel reduced pyridinium derivatives as synthetic cofactors for the enzyme DT diaphorase (NAD(P)H dehydrogenase (quinone), EC 1.6.99.2). Biochem Pharmacol 1992, 44: 25-31.
80. Knox, R.J., Freidlos, F., Jarman, M. et al. Virtual cofactors for an Escherichia coli nitroreductase enzyme: Relevance to reductively activated prodrugs in antibody directed enzyme prodrug therapy (ADEPT). Biochem Pharmacol 1995, 49: 1641-7.
81. Knox, R.J., Freidlos, F., Sherwood, R.F., Melton, R.G., Anlezark, G.M. The bioactivation of 5-(aziridinl-yl)-2,4-dinitrobenzamide (CB 1954) II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem Pharmacol 1992, 44: 2297-301.
82. Palmer, B.P., Wilson, W.R., Cliffe, S., Denny, W.A. Hypoxiaselective antitumour agents. 5. Synthesis of water soluble nitroaniline mustards with selective toxicity to hypoxic mammalian cells. J Med Chem 1992, 35: 3214-22.
83. Palmer, B.P., Wilson, W.R., Atwell, G.J., Schultz, D., Xu, X.Z., Denny, W.A. Hypoxia-selective antitumour agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-[N,N-bis(2-chloroethyl)amino]-2,4-dinitrobenzamide. J Med Chem 1994, 37: 2175-84.
84. Anlezark, G.M., Mellon, R.G., Sherwood, R.F. et al. Bioactivation of dinitrobenzamide mustards by an E. coli B nitroreductase. Biochem Pharmacol 1995, 50: 609-18.
85. Hay, M.P., Wilson, W.R., Denny, W.A. A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. coli B nitroreductase. Bioorg Med Chem Lett 1995, 5: 2829-34.
86. Tercel, M., Denny, W.A., Wilson, W.R. Bioorg Med Chem Lett, submitted.
87. Schultz, P.G., Lemer, R.A., Benkovic, S.J. Catalytic antibodies. Chem Eng News 1990, May 28: 26-40.
88. Campbell, D.A., Gong, B., Kochsperger, L.M., Yonkovich, S., Gallop, M.A., Schultz, P.G. Antibody-catalyzed prodrug activation. J Amer Chem Soc 1994, 116: 2165-6.
89. Bosslet, K., Czech, J., Lorenz, P., Sedlacek, H.H., Schuermann, M., Seeman, G., Molecular and functional characterization of a fusion protein suited for tumour specific prodrug activation. Brit J Cancer 1992, 65: 234-8.
90. Bosslet, K., Czech, J., Hoffmann, D. Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Res 1994, 54: 2151-9.
91. Bosslet, K., Czech, J., Seeman, G., Monneret, C., Hoffmann, D. Fusion protein mediated prodrug activation (FMPA) in vivo. Cell Biophys 1994, 24/25: 51-63.
92. Bristol-Myers Co. EP 484870A2.